Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Gu, Yunjuan ^a,b,c,d   Wang, Chunfang ^e   Zheng, Ying ^e   Hou, Xuhong ^a,c   Mo, Yifei ^a,b,c   Yu, Weihui ^a,b,c   Zhang, Lei ^a,c   Hu, Cheng ^a,c   Nan, Hairong ^f   Chen, Lei ^a,c   Li, Jie ^a,c   Liu, Yuxiang ^a,b,c   Huang, Zhezhou ^e   Han, Ming ^e   Bao, Yuqian ^a,c   Zhong, Weijian ^e   Jia, Weiping ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Key Laboratory of Diabetes Mellitus   (China)

^d NANTONG UNIVERSITY   (China)

^e Shanghai Municipal Center for Diseases Prevention and Control   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BRAIN DEATH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR MORTALITY; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREAS CANCER; RISK ASSESSMENT;

EID: 84872144498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053411     Document Type: Article

References (22)

1. Nicolucci A, (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47: 87-95.
2. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-221.
3. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
4. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52: 1745-1754.
5. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, et al. (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33: 1997-2003.
6. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744.
7. Colhoun HM, (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
8. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1971-1973.
9. Yang X, Ko GT, So WY, Ma RC, Yu LW, et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 59: 1254-1260.
10. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, et al. (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS One 6: e21368.
11. Tseng CH, (2012) Diabetes but not insulin is associated with higher colon cancer mortality. World J Gastroenterol 18: 4182-4190.
12. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328.
13. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sorensen R, et al. (2012) Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2.
14. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, (2012) Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97: E1170-1175.
15. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, et al. (2012) Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107: 46-52.
16. Heuson JC, Legros N, Heimann R, (1972) Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res 32: 233-238.
17. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R, (2009) Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123.
18. Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH, (2010) Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci 101: 65-72.
19. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, et al. (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335: 497.
20. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, et al. (2011) Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60: 1363-1371.
21. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
22. Seshasai SR, Kaptoge S, Thompson A, (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829-841.